{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:33:20Z","timestamp":1772789600483,"version":"3.50.1"},"reference-count":39,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals America, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2389005","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T14:03:37Z","timestamp":1722866617000},"page":"1076-1085","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3508-1296","authenticated-orcid":false,"given":"Victoria Federico","family":"Paly","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals America, Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujun","family":"Li","sequence":"additional","affiliation":[{"name":"Evidera","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-4423","authenticated-orcid":false,"given":"Pratishtha","family":"Khanduri","sequence":"additional","affiliation":[{"name":"Evidera","place":["Toronto, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-3510","authenticated-orcid":false,"given":"Alemseged Ayele","family":"Asfaw","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Zou","sequence":"additional","affiliation":[{"name":"Evidera","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9532-546X","authenticated-orcid":false,"given":"Luis","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America, Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"e_1_3_5_2_1","volume-title":"Cancer facts and figures 2023","author":"ACS","year":"2023","unstructured":"ACS. Cancer facts and figures 2023. Atlanta (GA): America Cancer Society; 2023."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.01.003"},{"key":"e_1_3_5_4_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program. Cancer Stat Facts: colorectal cancer; 2023 Oct 12. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32319-0"},{"key":"e_1_3_5_6_1","unstructured":"FRUZAQLA (fruquintinib) [package insert]. Lexington (MA): Takeda Pharmaceuticals America Inc.; 2023."},{"key":"e_1_3_5_7_1","unstructured":"FDA approves fruquintinib in refractory metastatic colorectal cancer [Internet]; 2023 Nov 8. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancer"},{"key":"e_1_3_5_8_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Colon Cancer. Version 4.2023\u2014November 16 2023; 2023."},{"key":"e_1_3_5_9_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Rectal Cancer. Version 6.2023\u2014November 16 2023; 2023."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_5_11_1","unstructured":"Institute for Clinical and Economic Review (ICER). ICER's reference case for economic evaluations: principles and rationale; 2020 [2023 Sep 22]. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2020\/01\/ICER_Reference_Case_013120.pdf"},{"key":"e_1_3_5_12_1","unstructured":"STIVARGA (regorafenib) [package insert]. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc.; 2017."},{"key":"e_1_3_5_13_1","unstructured":"LONSURF (trifluridine and tipiracil) [package insert]. Princeton (NJ): FTaiho Pharmaceutical Co. Ltd. Japan; 2023."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214963"},{"key":"e_1_3_5_15_1","unstructured":"Centers for Medicare & Medicaid Services. CMS Program Statistics\u2014Medicare Total Enrollment; 2023 [updated 2023 Mar 6; 2023 Aug 15]. Available from: https:\/\/data.cms.gov\/summary-statistics-on-beneficiary-enrollment\/medicare-and-medicaid-reports\/cms-program-statistics-medicare-total-enrollment"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-018-03227-5"},{"key":"e_1_3_5_17_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program; 2023 Aug 3. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html"},{"key":"e_1_3_5_18_1","unstructured":"National Cancer Institute. Recent trends in SEER age-adjusted incidence rates 2004-2020; 2023 [updated 2023 Jun 8; 2023 Aug 15]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.53"},{"key":"e_1_3_5_20_1","unstructured":"United States Census Bureau. Age and sex composition in the United States: 2021; 2021 [updated 2022 Oct 20; 2023 Aug 15]. Available from: https:\/\/www.census.gov\/data\/tables\/2021\/demo\/age-and-sex\/2021-age-sex-composition.html"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7855"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyy013"},{"issue":"1","key":"e_1_3_5_25_1","first-page":"1","article-title":"U.S. state life tables, 2018","volume":"70","author":"Arias E","year":"2021","unstructured":"Arias E, Bastian B, Xu J, et\u00a0al. U.S. state life tables, 2018. Natl Vital Stat Rep. 2021;70(1):1\u201317.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_5_26_1","unstructured":"Merative Micromedex \u00ae RED BOOK \u00ae micromedexsolutions.com; 2023 [cited 2023 Apr 24 2023 for all prices except frquintinib which was accessed on November 15]."},{"key":"e_1_3_5_27_1","unstructured":"Centers for Medicare & Medicaid Services. Q2-April 2023 Average Sales Price (ASP) Pricing File; 2023 [2023 Apr 24]."},{"key":"e_1_3_5_28_1","unstructured":"Practice Management Information Corporation (PMIC). Medical Fees Directory 2023\u2014eBook. Usual customary and reasonable (UCR) fees."},{"key":"e_1_3_5_29_1","unstructured":"CMS.gov. Physician fee schedule look-up tool. National Payment Amount by HCPCS Code. [cited Apr 2023]."},{"key":"e_1_3_5_30_1","unstructured":"HCUPnet. 2020 National inpatient statistics by principal diagnosis\u2013Clinical Classification Software Refined (CCSR). [cited Apr 2023]."},{"key":"e_1_3_5_31_1","unstructured":"CMS.gov. Medicare acute inpatient PPS. IPPS Final Rule Home Page: DRG Payment per Stay. FY; 2023."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0018"},{"key":"e_1_3_5_33_1","unstructured":"Claxton G Rae M Ochieng N et\u00a0al. Comparing private payer and medicare payment rates for select inpatient hospital services; 2020 [2023 Sep 29]. Available from: https:\/\/www.kff.org\/medicare\/issue-brief\/comparing-private-payer-and-medicare-payment-rates-for-select-inpatient-hospital-services\/"},{"key":"e_1_3_5_34_1","unstructured":"MedPAC Chapter 10: Hospice services. (March 2023 Report); 2023 Sept 22. Available from: https:\/\/www.medpac.gov\/wp-content\/uploads\/2023\/03\/Ch10_Mar23_MedPAC_Report_To_Congress_SEC.pdf"},{"key":"e_1_3_5_35_1","unstructured":"Worstell C. Medicare statistics; 2023 [cited 2023 Dec 7]. Available from: https:\/\/www.medicareadvantage.com\/resources\/medicare-statistics"},{"key":"e_1_3_5_36_1","unstructured":"Institute for Clinical and Economic Review (ICER). Value assessment framework [cited 2023 Dec 7]. Available from: https:\/\/icer.org\/our-approach\/methods-process\/value-assessment-framework\/"},{"key":"e_1_3_5_37_1","unstructured":"Institute for Clinical and Economic Review (ICER). Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive non-muscle invasive bladder cancer: effectiveness and value; 2020 [updated 2021 Jan 15; cited 2023 Dec 7]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/08\/ICER_Bladder_Cancer_Final_Report_07292022.pdf"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.02.003"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21728"},{"key":"e_1_3_5_40_1","unstructured":"United States Census Bureau. Estimates of the total resident population and resident population age 18 years and older for the United States Regions States District of Columbia and Puerto Rico: July 1 2022; 2022 [2023 Oct 12]. Available from: https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2020s-national-detail.html"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2389005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:44:33Z","timestamp":1772779473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2389005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2389005"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2389005","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}